Published in Oncology Business Week, April 3rd, 2005
The company's in house drug discovery intellectual property portfolio has been built on over 10 years of extensive collaborative academic research related to the role of heparan sulfate, a complex sugar implicated in several disease processes.
The primary objective of this research, supported by an Australian $3.1M AusIndustry START grant, is focused towards building the company's future internal drug pipeline and in house efforts are augmented by collaboration with Martin Banwell...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Oncology Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.